Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REMfresh is a continuous release and absorption (CRA) melatonin supplement designed to address occasional sleeplessness and sleep maintenance issues. Developed by Physician's Seal and marketed by Nestlé, it utilizes a patented Ion Powered Pump (IPP) delivery technology to release 99% ultrapure melatonin (branded as Ultramel) continuously for up to 7 hours. This delivery profile is intended to mimic the body's natural 'Mesa Wave' pattern of melatonin secretion, which typically peaks in the middle of the night. As a non-prescription dietary supplement, it targets endogenous melatonin receptors to regulate the circadian rhythm and improve sleep quality without the grogginess often associated with immediate-release sleep aids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on REMfresh.